Immunogenicity of the BNT162b2 messenger RNA vaccine in patients with AIIRD and controls
| Study participants, n | Seropositivity rate, n (% of total) | Serum anti-S1/S2 IgG titre, mean±SD, BAU/mL |
| Controls, n=121 | 121 (100) | 218.6±82.06 |
| Patients with AIIRD, n=686 | 590 (86.0)* | 132.9±91.7* |
| RA, n=263 | 216 (82.1) | 108.7±84.7 |
| PsA, n=165 | 160 (96.9) | 162.0±71.7 |
| AxSpA, n=68 | 67 (98.5) | 173.1±90.1 |
| SLE, n=101 | 93 (92.1) | 161.9±105.2 |
| IIM, n=19 | 7 (36.8) | 42.9±62.6 |
| LVV, n=21 | 20 (95.2) | 143.3±84.6 |
| AAV, n=26 | 8 (30.8) | 40.3±73.2 |
| Other vasculitis, n=23 | 19 (86.6) | 122.7±87.9 |
*p<0.0001.
AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; AIIRD, autoimmune inflammatory rheumatic diseases; AxSpA, axial spondyloarthritis; BAU, binding antibody units; IIM, idiopathic inflammatory myositis; LVV, large vessel vasculitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.